PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT • 2.1 Preface • 2.2 Preface • 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 04: MARKET SIZING • Market definition • Market sizing 2018 • Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 06: MARKET SEGMENTATION BY PRODUCT • Market segmentation by product • Comparison by product • MEKINIST - Market size and forecast 2018-2023 • COTELLIC - Market size and forecast 2018-2023 • MEKTOVI - Market size and forecast 2018-2023 • Market opportunity by product PART 07: CUSTOMER LANDSCAPE PART 08: GEOGRAPHIC LANDSCAPE • Geographic segmentation • Geographic comparison • North America - Market size and forecast 2018-2023 • Europe - Market size and forecast 2018-2023 • Asia - Market size and forecast 2018-2023 • ROW - Market size and forecast 2018-2023 • Key leading countries • Market opportunity PART 09: DECISION FRAMEWORK PART 10: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 11: MARKET TRENDS • Special drug designations • Expanded application • Use of protein biomarkers in diagnosis of NSCLC PART 12: VENDOR LANDSCAPE • Overview • Landscape disruption • Competitive scenario PART 13: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • AstraZeneca Plc • F. Hoffmann-La Roche Ltd. • Novartis AG • Ono Pharmaceutical Co. Ltd. • Pfizer Inc. PART 14: APPENDIX • Research methodology • List of abbreviations • Definition of market positioning of vendors PART 15: EXPLORE TECHNAVIO   Exhibit 01: Product overview Exhibit 02: Global pharmaceuticals market Exhibit 03: Segments of global pharmaceuticals market Exhibit 04: Market characteristics Exhibit 05: Market segments Exhibit 06: Market definition - Inclusions and exclusions checklist Exhibit 07: Market size 2018 Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 09: Global market: Year-over-year growth 2019-2023 (%) Exhibit 10: Five forces analysis 2018 Exhibit 11: Five forces analysis 2023 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition - Five forces 2018 Exhibit 18: Product - Market share 2018-2023 (%) Exhibit 19: Comparison by product Exhibit 20: MEKINIST - Market size and forecast 2018-2023 ($ millions) Exhibit 21: MEKINIST - Year-over-year growth 2019-2023 (%) Exhibit 22: COTELLIC - Market size and forecast 2018-2023 ($ millions) Exhibit 23: COTELLIC - Year-over-year growth 2019-2023 (%) Exhibit 24: MEKTOVI - Market size and forecast 2018-2023 ($ millions) Exhibit 25: MEKTOVI - Year-over-year growth 2019-2023 (%) Exhibit 26: Market opportunity by product Exhibit 27: Customer landscape Exhibit 28: Market share by geography 2018-2023 (%) Exhibit 29: Geographic comparison Exhibit 30: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 31: North America - Year-over-year growth 2019-2023 (%) Exhibit 32: Top 3 countries in North America Exhibit 33: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 34: Country-wise age-standardized rate of melanomas in Europe 2018 Exhibit 35: Country-wise prevalence rate of NSCLC in Europe 2008 Exhibit 36: Europe - Year-over-year growth 2019-2023 (%) Exhibit 37: Top 3 countries in Europe Exhibit 38: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 39: Asia - Year-over-year growth 2019-2023 (%) Exhibit 40: Top 3 countries in Asia Exhibit 41: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 42: ROW - Year-over-year growth 2019-2023 (%) Exhibit 43: Top 3 countries in ROW Exhibit 44: Key leading countries Exhibit 45: Market opportunity Exhibit 46: Alternative therapies based on MEK inhibitors for various oncology indications Exhibit 47: Side effects of MEK and BRAF inhibitors Exhibit 48: Impact of drivers and challenges Exhibit 49: Drug designations Exhibit 50: Vendor landscape Exhibit 51: Landscape disruption Exhibit 52: Vendors covered Exhibit 53: Vendor classification Exhibit 54: Market positioning of vendors Exhibit 55: AstraZeneca Plc - Vendor overview Exhibit 56: AstraZeneca Plc - Business segments Exhibit 57: AstraZeneca Plc - Organizational developments Exhibit 58: AstraZeneca Plc - Geographic focus Exhibit 59: AstraZeneca Plc - Key offerings Exhibit 60: AstraZeneca Plc - Key customers Exhibit 61: F. Hoffmann-La Roche Ltd. - Vendor overview Exhibit 62: F. Hoffmann-La Roche Ltd. - Business segments Exhibit 63: F. Hoffmann-La Roche Ltd. - Organizational developments Exhibit 64: F. Hoffmann-La Roche Ltd. - Geographic focus Exhibit 65: F. Hoffmann-La Roche Ltd. - Segment focus Exhibit 66: F. Hoffmann-La Roche Ltd. - Key offerings Exhibit 67: F. Hoffmann-La Roche Ltd. - Key customers Exhibit 68: Novartis AG - Vendor overview Exhibit 69: Novartis AG - Business segments Exhibit 70: Novartis AG - Organizational developments Exhibit 71: Novartis AG - Geographic focus Exhibit 72: Novartis AG - Segment focus Exhibit 73: Novartis AG - Key offerings Exhibit 74: Novartis AG - Key customers Exhibit 75: Ono Pharmaceutical Co. Ltd. - Vendor overview Exhibit 76: Ono Pharmaceutical Co. Ltd. - Business segments Exhibit 77: Ono Pharmaceutical Co. Ltd. - Organizational developments Exhibit 78: Ono Pharmaceutical Co. Ltd. - Geographic focus Exhibit 79: Ono Pharmaceutical Co. Ltd. - Key offerings Exhibit 80: Ono Pharmaceutical Co. Ltd. - Key customers Exhibit 81: Pfizer Inc. - Vendor overview Exhibit 82: Pfizer Inc. - Business segments Exhibit 83: Pfizer Inc. - Organizational developments Exhibit 84: Pfizer Inc. - Geographic focus Exhibit 85: Pfizer Inc. - Segment focus Exhibit 86: Pfizer Inc. - Key offerings Exhibit 87: Pfizer Inc. - Key customers Exhibit 88: Validation techniques employed for market sizing Exhibit 89: Definition of market positioning of vendors

AstraZeneca Plc, F. Hoffmann-La Roche Ltd., Novartis AG, Ono Pharmaceutical Co. Ltd., and Pfizer Inc.